According to DRG epidemiology, more than 35 million people in the United States suffer migraines. Migraine prophylaxis, though underused, is a core treatment approach to reduce migraine frequency, severity, and duration. Prescription options include a diverse mix of on- and off-label oral drugs, as well as Allergan’s Botox, approved specifically for chronic migraine. Prophylaxis is both individualized and dynamic as physicians adjust regimens to improve outcomes or avoid side effects. Understanding this patient journey provides needed context for new and existing players as next-generation preventives race to market.

Questions Answered

  • What patient share do key therapies and brands garner by line of therapy in migraine patients initiating prophylaxis? What are the quarterly trends in prescribing among recently treated and prophylactically naive migraine patients?
  • How has Botox been integrated into the treatment algorithm?
  • What proportion of prophylactically naive migraine patients receives preventive therapy within our prescription tracking period, and how quickly? What percentage of patients progress to later lines of therapy after initiating a prophylactic regimen?
  • What percentage of migraine patients are treated with prophylaxis monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among migraine patients treated with prescription prophylactic therapies?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs: Botox, topiramate IR, Trokeni XR, Qudexy XR, topiramate XR, propranolol, amitriptyline, verapamil, others

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.

Related Reports

Migraine - Unmet Need - Detailed, Expanded Analysis Acute Migraine

A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings...

View Details

Migraine - Geographic Focus - China - Migraine | China In-Depth | China

Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s n...

View Details

Migraine - Access & Reimbursement - Detailed, Expanded Analysis (US) - Acute Migraine

2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec

View Details

Migraine - Landscape & Forecast - Disease Landscape & Forecast

The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the l...

View Details